Entry level $22.25 = Target price $28.00 = Stop loss $21.00 Trade the huge gap in the chart Stock is well below its average analysts price target @$31 and overweight rating. Short interest 19.87% fuel a recovery rally. Company profile Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug...
Earnings beat yesterday with positive mobility in R&D, plus the regulatory committee has resumed inquiries that were previously placed on hold.
With all the opioid lawsuits against drug manufactors NKTR stands as a clear choice for massive future gains. Why? NKTR has made a non-addictive opioid pending FDA Approval. Everyday 130 people die from overdosing on some form of opioid which is why creating a safe, non-addictive opioid is a huge feat. This stock is at an incredible value, and the risk v reward...
NKTR’s innovation outlook is trending down based on a current score of 60 out of 99, outperforming sector average. Insiders sentiment is negative. Over the past 4 quarters NKTR beat earnings estimates 4 times. For more analysis and articles visit our website.
No doubt about this bear flag, targeting 15,70$?
NKTR is a bio-pharmaceutical company that has a large pipeline. News: July 25th FDA issues letter postponing a Advisory Committee meeting (ADCOM) on their pain relief drug, the postponement is not related to the specific drug itself price drops. Aug 1st: Breakthrough Therapy Designation given for metastatic melanoma drug Aug 8th Earnings Report - expect a sell...
Although this seems to be a risky long trade. The reward is looking promising. Looking at the fundamentals, this company is well positioned with Cash. Debt is manageable even though the company is burning through cash (but that what most healthcare companies do until their products get FDA approval). Targets and Stops are in the graphic.
Long term trend : uptrend on the monthly chart. Short term trend : downtrend on a weekly chart. Chart formation : price coiling with support formation; reversal formation on the daily chart Supply and demand : overbought with low stochastics Opportunity : long-term BUY. Can buy now or wait for the price to retrace 1 more time towards 32. Rules : Always...
The stock of NKTR has been setting up nicely for a breakout and June 13th could be the day it happens, as the company will be hosting a analysts conference call to discuss trial results/data. Keep on strong watch for explosive moves. AVERAGE ANALYSTS PRICE TARGET $69.50 AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT SHORT INTEREST 12.65% P/E RATIO 9.54 Nektar...
If you believe the analysts stating $NKTR above $70/share within 12 months, now would be the time to consider jumping in. You may be able to wait for lower pricing throughout the week, yet the zones are set to rise in a couple weeks. Not financial advice. Read prior ideas and you'll see I've been bearish for a bit. Enjoy.
Can't get back above 0 on MACD. Can't get back above 50 on Stoch RSI. TradingNewsNow claims an intrinsic value per share above $130. Results and Presentations seem to not be helping. I'd "like" to see $41/share, but $24/share might be more the direction of Nektar Therapeutics before a rebound. Continuing to watch sideways movements between $30-$37 in the meantime....
A prior chart, a new perspective, added analysis, down or sideways? I see more downside, yet, sideways looks plausible. Upside maybe 20% chance to $42 by June. Enjoy the chart.
After less than stellar results released last week, $NKTR drops. What do earnings look like? Guess we'll see. Charts gain my interest. $46 - $48 on the upside, $33 - $38 short term? NOT FINANCIAL ADVICE. JUST A WATCHER.
My chart is getting a bit messy, however, this one does shoe a consistent pattern on both MACD and Stochastic RSI, making this either the BEST time to BUY, or the WORST time to BUY. It may break $50/share by the end of summer, and End of February Earnings could rebound the stock up to $70+ on the Bullish Side over 3-6 months. On the Bearish side, I am still...